Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

These days, many devices are programmed through apps on patients’ phones. But the FDA warns that certain phone settings, such ...

Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even before symptoms occur.

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Medha N. Munshi, MD, a geriatrician and endocrinologist at Beth Israel Deaconess Medical Center, has dedicated her career to improving care for older adults. In 2001, she founded the Geriatric ...

Dear Just Turned 63: Everyone with high blood pressure (130/80 or above) should have a home blood pressure monitor. Home ...

Researchers have devised a revolutionary, noninvasive method to monitor blood glucose, allowing for accurate measurements of ...

Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin.

Shanghai's Ruijin Hospital announced today that researchers have developed a groundbreaking non-invasive blood glucose ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

While prediabetes carries an increased risk of developing type 2 diabetes, Diabetes UK emphasizes that it can be reversed ...